Episurf Medical announced that all patients have been recruited to a prospective clinical study on the Episealer Talus implant, led by Prof. Stefano Zaffagnini, from the Rizzoli Orthopaedic Institute in Bologna, Italy, supported by Dr Massimiliano Mosca and Prof. Niek van Dijk. The study will follow 20 patients who received an Episealer Talus® implant as treatment for osteochondral defects in their ankle joint. Episealer® Talus is Episurf Medical's CE marked implant technology, intended for the treatment of ankle lesions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.359 SEK | -2.45% | -49.44% | -63.74% |
Apr. 24 | Episurf Medical Announces Distributor Agreement with Depuy-Synthes | CI |
Apr. 24 | Episurf Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-63.74% | 8.76M | |
+12.07% | 128B | |
-9.04% | 10.65B | |
+0.91% | 8.82B | |
+16.72% | 7.19B | |
+25.15% | 4.99B | |
+7.17% | 3.4B | |
-1.36% | 3.03B | |
-8.73% | 2.14B | |
-10.15% | 2B |
- Stock Market
- Equities
- EPIS B Stock
- News Episurf Medical AB
- Episurf Medical Announces Prospective Episealer Talus Clinical Study